Dapagliflozin 10S

About

Dapagliflozin 10S contains Dapagliflozin, an oral antidiabetic medication belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily used in the management of type 2 diabetes mellitus, and increasingly for heart failure and chronic kidney disease. Dapagliflozin works by inhibiting SGLT2 in the renal tubules, which reduces the reabsorption of glucose from the filtered fluid back into the bloodstream. This leads to increased urinary glucose excretion, thereby lowering blood glucose levels independently of insulin.

Beyond its glycemic control effects, dapagliflozin has demonstrated significant cardiovascular and renal benefits, including a reduction in the risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease. Its unique mechanism of action makes it a valuable therapeutic option for a broad range of patients.

Uses

• Management of type 2 diabetes mellitus.
• Reduction of cardiovascular death and hospitalization for heart failure.
• Reduction of the risk of end-stage kidney disease.
• Adjunct to diet and exercise for glycemic control.

Directions For Use

Take one tablet orally once daily in the morning, with or without food, as directed by your physician.

Benefits

• Effective blood glucose lowering.
• Reduces risk of cardiovascular events.
• Slows progression of kidney disease.
• Promotes modest weight loss.
• Low risk of hypoglycemia when used alone.
• Blood pressure reduction.

Side Effects

• Genital mycotic infections
• Urinary tract infections
• Increased urination
• Thirst
• Dizziness
• Hypotension
• Ketoacidosis (rare)
• Renal impairment (acute)
• Back pain
• Dyslipidemia
• Flu-like symptoms
• Hypoglycemia (when combined with insulin/sulfonylureas)

Safety Measures

• Alcohol - Excessive alcohol consumption may increase the risk of diabetic ketoacidosis, a serious side effect, especially in patients taking SGLT2 inhibitors. Limit alcohol intake.
• Pregnancy - Dapagliflozin is not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal renal development. Use in the first trimester is generally avoided.
• Breastfeeding - It is unknown if dapagliflozin is excreted in human milk. Due to the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended.
• Liver - No dose adjustment is required in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to limited experience.
• Kidney - Not recommended for use in patients with severe renal impairment (eGFR <25 mL/min/1.73 m²) or end-stage renal disease. Dose adjustments may be needed based on eGFR.
• Lung - Generally safe for use in patients with lung conditions. However, dehydration caused by the drug could potentially exacerbate conditions in very fragile patients.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.